BenevolentAI

News

BenevolentAI CEO steps down as founders make a comeback

Jörg Möller's sojourn as chief executive of BenevolentAI has come to an abrupt end after just nine months, as the company names co-founder Ken Mulvany as its executive chairman.

Digital

Recursion, Exscientia, and AI drug discovery’s moment of tru...

Last week, two of the biggest and oldest companies in the burgeoning AI drug discovery space announced a surprise merger.

News

Shakeup at BenevolentAI continues with job, programme cuts

BenevolentAI is embarking on another round of job losses, closing its US office, and shelving its software-as-a-service business to extend its cash reserves into the third

News

BenevolentAI names pharma vet Jörg Möller as its new CEO

BenevolentAI’s search for a new chief executive has concluded with the appointment of industry bigwig Dr Jörg Möller to the role, four months after Joanna Shields stepped

News

Merck puts $1.3bn into AI via Exscientia, BenevolentAI deals

German group Merck has revved up its artificial intelligence-powered drug discovery with partnerships with two UK companies – Exscientia and BenevolentAI – that will focus

News